Article in eLife, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 5 institutions in 1 country.
Ellen PhillipsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.ORCID 0000-0003-3654-2066
Naseer AhmadDepartments of Medicine and Pharmacological Sciences and Center for translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, United States.ORCID 0000-0001-9514-2703
Li SunDepartments of Medicine and Pharmacological Sciences and Center for translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, United States.
James IbenMolecular Genomics Core, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, United States.
Christopher J WalkeyDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
Aleksandra RusinDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.
Tony YuenDepartments of Medicine and Pharmacological Sciences and Center for translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, United States.
Clifford J RosenCenter for Clinical and Translational Research, Maine Medical Center Research Institute, Scarborough, United States.
Ian M WillisDepartments of Biochemistry and Systems and Computational Biology, Albert Einstein College of Medicine, Bronx, United States.ORCID 0000-0001-6599-2395
Mone ZaidiDepartments of Medicine and Pharmacological Sciences and Center for translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, United States.ORCID 0000-0001-5911-9522
Deborah L JohnsonDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, United States.ORCID 0000-0003-1745-1580
Baylor College of Medicine · USIcahn School of Medicine at Mount Sinai · USAlbert Einstein College of Medicine · USMaine Medical Center Research Institute · USNational Institutes of Health · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9M
Targeting FSH for the Therapy of Osteoporosis, Obesity and NeurodegenerationU19AG060917 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Mone Zaidi · 2019 to 2026
$29.0M
A Humanized Monoclonal FSH Blocking Antibody for Alzheimer's DiseaseU01AG073148 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Tony Yuen, Mone Zaidi · 2021 to 2026
$10.6M
SUPPORT FOR THE ROSE F KENNEDY IDDRC P50P50HD105352 · NICHD · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SOPHIE MOLHOLM, Steven Upshaw Walkley · 2021 to 2026
$7.0M
Elevated FSH - A Driver for Sex Differences in Alzheimer's DiseaseR01AG074092 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HAROUTUNIAN, VAHRAM, YUEN, TONY · 2021 to 2025
$6.3M
Proof-of-Concept and Mechanistic Studies to Repurpose Erectile Dysfunction Drugs for Elderly FemalesR01AG071870 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KIM, SE-MIN, YUEN, TONY · 2021 to 2025
$3.9M
TATA-binding protein, a novel target of EGFR signalingR01CA074138 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOHNSON, DEBORAH L. · 1997 to 2015
$3.6M
Novel targets that are deregulated by loss of PTENR01CA108614 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JOHNSON, DEBORAH L. · 2006 to 2016
$2.7M
MAF1 Function and Metabolic InefficiencyR01GM120358 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI WILLIS, IAN M · 2016 to 2019
MAF1, a key repressor of RNA polymerase (pol) III-mediated transcription, has been shown to promote mesoderm formation in vitro. Here, we show that MAF1 plays a critical role in regulating osteoblast differentiation and bone mass. Global deletion of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
MAF1, a repressor of RNA polymerase III-dependent transcription, regulates bone mass. · full record | OpenQuestion